CompletedPhase 3NCT02548143
LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Principal Investigator
- Miguel Escobar, MDMemorial Hermann Texas Medical Center
- Intervention
- Coagulation Factor VIIa (Recombinant)(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 75 years · MALE
- Timeline
- 2016 – 2017
Study locations (9)
- UT Southwestern Medical Center, Dallas, Texas, United States
- Dr. Jose Eleuterio Gonzalez Monterrey University Hospital, Monterrey, Nuevo León, Mexico
- Hematology Research Center of the Russian Academy of Medical Sciences, Moscow, Russia
- Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care, Parktown, Gauteng, South Africa
- Worthwhile Clinical Trials, Lakeview Hospital, Benoni, South Africa
- University and Polytechnic Hospital La Fe, Hemostasis and Thrombosis Unit, Valencia, Spain
- City Scientific-Practical center for diagnosics, Kiev, Ukraine
- National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology, Kyiv, Ukraine
- Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine
Collaborators
LFB USA, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02548143 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota